Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 17

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
, through the date these consolidated financial statements were issued.

13

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial
condition and results of operations This discussion contains forward-looking statements that involve risks and uncertainties. Our actual
results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are
not limited to, those discussed above under “Cautionary Note Regarding Forward-Looking Statements,” and in Item 1A. Risk factors
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Overview

Imunon is a clinical-stage biotechnology company focused
on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective
and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon
is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins
and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®,
is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising
platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical development studies.
IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12
and interferon gamma, at the tumor site. Additionally, the Company has entered into a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients
with difficult-to-treat conditions.

Technology Platform

Imunon’s technology platform is optimized for
the delivery of DNA and mRNA therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded
DNA plasmids and large therapeutic RNA segments such as mRNA. There are two components to the system, a backbone with plasmid DNA or mRNA
payload encoding therapeutic proteins, or pathogen antigens